Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 8/20 | 0.56 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865180 | 0.89 | MGLL (0.42) | MGLLPLA2G7ABHD6C5AR1FAAH | |
| SCHEMBL30865142 | 0.85 | MGLL (0.56) | MGLLCYP3A4CYP2D6IDO1 | |
| SCHEMBL30865410 | 0.84 | MGLL (0.57) | MGLL | |
| SCHEMBL30865165 | 0.82 | MGLL (0.55) | MGLL | |
| SCHEMBL30865321 | 0.82 | MGLL (0.55) | MGLLCYP3A4CYP2D6IDO1FAAH | |
| SCHEMBL30865430 | 0.82 | MGLL (0.53) | MGLLC5AR1 | |
| SCHEMBL30865244 | 0.81 | MGLL (0.54) | MGLLCYP3A4CYP2D6IDO1 | |
| SCHEMBL30865183 | 0.81 | MGLL (0.57) | MGLLCYP3A4CYP2D6IDO1 | |
| SCHEMBL30865159 | 0.81 | MGLL (0.65) | MGLLCYP3A4CYP2D6IDO1 | |
| SCHEMBL25325015 | 0.81 | MGLL (0.39) | MGLLPLA2G7ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608823-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | claimed |
| WO-2024088922-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-02 | — | — | WO | claimed |
| EP-4608823-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. Hoffmann-La Roche AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024088922-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-02 | — | — | WO | disclosed |